#	Pagina
attuale pagina	/open-h2020/projects/212500/index.html

Opendata, web and dolomites

DIDO-MS

Commercialization of a first in class multiple sclerosis drug

Total Cost €

EC-Contrib. €

Partnership

Views

DIDO-MS project word cloud

Explore the words cloud of the DIDO-MS project. It provides you a very rough idea of what is the project "DIDO-MS" about.

regions predicts canada limited ms routes primarily intramuscular markets progressive sclerosis chronic cancer multiple china japan approved risks market patients efficacies 12 82 prevent severe economically drug hemisphere million incidence 18 small afflicted burden italy options intravenous molecule unable people subcutaneous globaldata newly administration spain france young viability ranging northern commercial aside sales economic germany 16 productive treatment treatments society india infection drugs lies billion neurodegeneration disease approximately worldwide 700 projected attributed lack located 2014 shortcoming significantly rates neurodegenerative uk ultimately efficacy 2024 poses inconvenient dido

Project "DIDO-MS" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITA DEGLI STUDI DI PERUGIA Organization address address: PIAZZA DELL UNIVERSITA 1 city: PERUGIA postcode: 6123 website: www.unipg.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Total cost	150˙000 €
EC max contribution	150˙000 € (100%)
Programme	1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
Code Call	ERC-2017-PoC
Funding Scheme	ERC-POC
Starting year	2018
Duration (year-month-day)	from 2018-02-01 to 2019-07-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSITA DEGLI STUDI DI PERUGIA UNIVERSITA DEGLI STUDI DI PERUGIA Organization address address: PIAZZA DELL UNIVERSITA 1 city: PERUGIA postcode: 6123 website: www.unipg.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (PERUGIA)	coordinator	150˙000.00

Map

Project objective

Multiple sclerosis (MS) is a chronic and progressive neurodegenerative disease that is currently affecting 2.3 million people worldwide. Incidence rates of MS are significantly higher in Europe and in other regions located within the northern hemisphere. In Europe, the number of patients currently afflicted with MS is estimated to be at 700,000, with incidence rates ranging from 2.3-12.2/100,000 per year. GlobalData assessed the market value for MS treatments in 10 major markets (France, Germany, Italy, Spain, UK, US, Canada, Japan, China and India) in 2014 to be at €16.2 billion and predicts it to rise to approximately €18.82 billion by 2024. This increase is attributed to the projected sales of newly-approved drugs. The main shortcoming of current MS treatments ultimately lies in their lack of efficacy, specifically in that they are unable to prevent progressive neurodegeneration in MS patients. MS poses a significant economic burden on society as the disease affects primarily young people who are in their most economically-productive years. Aside from limited efficacies, current treatment options are also associated with severe side-effects (increased risks of infection, cancer), high costs and inconvenient administration routes (e.g. intravenous, intramuscular, subcutaneous). The aim of DIDO-MS is to assess the commercial viability of a newly identified small molecule as a drug in the treatment of MS.

Publications

List of publications.
year	authors and title	journal	last update
2019	Marco Gargaro, Carmine Vacca, Serena Massari, Giulia Scalisi, Giorgia Manni, Giada Mondanelli, Emilia M. C. Mazza, Silvio Bicciato, Maria T. Pallotta, Ciriana Orabona, Maria L. Belladonna, Claudia Volpi, Roberta Bianchi, Davide Matino, Alberta Iacono, Eleonora Panfili, Elisa Proietti, Ioana Maria Iamandii, Violetta Cecchetti, Paolo Puccetti, Oriana Tabarrini, Francesca Fallarino, Ursula Grohmann Engagement of Nuclear Coactivator 7 by 3-Hydroxyanthranilic Acid Enhances Activation of Aryl Hydrocarbon Receptor in Immunoregulatory Dendritic Cells published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2019.01973	Frontiers in Immunology 10	2020-01-27
2019	Giada Mondanelli, Alberta Iacono, Massimo Allegrucci, Paolo Puccetti, Ursula Grohmann Immunoregulatory Interplay Between Arginine and Tryptophan Metabolism in Health and Disease published pages: 1565, ISSN: 1664-3224, DOI: 10.3389/fimmu.2019.01565	Frontiers in Immunology 10	2020-01-27
2019	Claudia Volpi, Ciriana Orabona, Antonio Macchiarulo, Roberta Bianchi, Paolo Puccetti, Ursula Grohmann Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis published pages: 1-14, ISSN: 1746-0441, DOI: 10.1080/17460441.2019.1646244	Expert Opinion on Drug Discovery 7	2020-01-27
2019	Giada Mondanelli, Alberta Iacono, Agostinho Carvalho, Ciriana Orabona, Claudia Volpi, Maria T. Pallotta, Davide Matino, Susanna Esposito, Ursula Grohmann Amino acid metabolism as drug target in autoimmune diseases published pages: 334-348, ISSN: 1568-9972, DOI: 10.1016/j.autrev.2019.02.004	Autoimmunity Reviews 18/4	2020-01-27

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DIDO-MS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DIDO-MS" are provided by the European Opendata Portal: CORDIS opendata.